Pharmacogenetic considerations in the treatment of co-infections with HIV/AIDS, tuberculosis and malaria in Congolese populations of Central Africa

International Journal of Infectious Diseases

Thirumalaisamy P. Velavan¹  Véronique Penlap Beng²  Peter G. Kremsner³  Mathew Bates⁴  Frederick Nchang Cho⁵  Darrel Ornelle Elion Assiana⁶  Gauthier Mesia Kahunu⁶  Kaossarath Adédjokè Fagbemi⁶  Le Thi Kieu Linh⁷  Christian G. Meyer⁸  Eric A. Achidi⁸  Ayola Akim Adegnika⁸  Martin P. Grobusch⁸  Srinivas Reddy Pallerla⁸  Francine Ntoumi⁸ 

[1] Centre de Recherches Medicales de Lambarene, Lambarene, Gabon;Department of Biochemistry and Molecular Biology, Faculty of Science, Laboratory of Infectious Diseases, Faculty of Health Sciences, University of Buea, Buea, Cameroon;Department of Biomedical Sciences, Laboratory of Cytogenetics and Medical Genetics, Faculty of Health Sciences, University of Abomey-Calavi, Benin;Faculty of Medicine, Duy Tan University, Da Nang, Viet Nam;Faculty of Sciences and Technology, University Marien Ngouabi, Brazzaville, Congo;Vietnamese-German Center for Medical Research, VG-CARE, Hanoi, Viet Nam;Fondation Congolaise pour la Recherche Médicale (FCRM), Brazzaville, Congo;Institute of Tropical Medicine, University of Tübingen, Wilhelmstrasse 27, 72074 Tübingen, Germany;

关键词: Malaria;    Tuberculosis;    HIV;    Pharmacogenetics;    Republic of Congo;   

DOI  :  

来源: DOAJ

【 摘 要 】

Background: HIV-infection, tuberculosis and malaria are the big three communicable diseases that plague sub-Saharan Africa. If these diseases occur as co-morbidities they require polypharmacy, which may lead to severe drug–drug-gene interactions and variation in adverse drug reactions, but also in treatment outcomes. Polymorphisms in genes encoding drug-metabolizing enzymes are the major cause of these variations, but such polymorphisms may support the prediction of drug efficacy and toxicity. There is little information on allele frequencies of pharmacogenetic variants of enzymes involved in the metabolism of drugs used to treat HIV-infection, TB and malaria in the Republic of Congo (ROC). The aim of this study was therefore to investigate the occurrence and allele frequencies of 32 pharmacogenetic variants localized in absorption distribution, metabolism and excretion (ADME) and non-ADME genes and to compare the frequencies with population data of Africans and non-Africans derived from the 1000 Genomes Project. Results: We found significant differences in the allele frequencies of many of the variants when comparing the findings from ROC with those of non-African populations. On the other hand, only a few variants showed significant differences in their allele frequencies when comparing ROC with other African populations. In addition, considerable differences in the allele frequencies of the pharmacogenetic variants among the African populations were observed. Conclusions: The findings contribute to the understanding of pharmacogenetic variants involved in the metabolism of drugs used to treat HIV-infection, TB and malaria in ROC and their diversity in different populations. Such knowledge helps to predict drug efficacy, toxicity and ADRs and to inform individual and population-based decisions.

【 授权许可】

Unknown